A150840 Stock Overview
IntroMedic Co., Ltd. develops and supplies medical equipment in South Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
IntroMedic Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩5,850.00 |
| 52 Week High | ₩8,220.00 |
| 52 Week Low | ₩2,460.00 |
| Beta | 0.40 |
| 11 Month Change | 0% |
| 3 Month Change | -4.26% |
| 1 Year Change | 136.36% |
| 33 Year Change | 6.36% |
| 5 Year Change | 70.31% |
| Change since IPO | 105.26% |
Recent News & Updates
Shareholder Returns
| A150840 | KR Medical Equipment | KR Market | |
|---|---|---|---|
| 7D | 0% | -4.1% | -5.4% |
| 1Y | 136.4% | 8.8% | -3.8% |
Return vs Industry: A150840 exceeded the KR Medical Equipment industry which returned 10.8% over the past year.
Return vs Market: A150840 exceeded the KR Market which returned 8% over the past year.
Price Volatility
| A150840 volatility | |
|---|---|
| A150840 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.0% |
| 10% least volatile stocks in KR Market | 3.5% |
Stable Share Price: A150840 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine A150840's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 54 | Yong Seok Cho | www.intromedic.com |
IntroMedic Co., Ltd. develops and supplies medical equipment in South Korea and internationally. It offers MiroCam, a capsule endoscope system; E.G. Scan, a disposable ductile esophagoscope; and EndoClot, an absorbent hemostasis equipment.
IntroMedic Co., Ltd. Fundamentals Summary
| A150840 fundamental statistics | |
|---|---|
| Market cap | ₩223.67b |
| Earnings (TTM) | -₩15.52b |
| Revenue (TTM) | ₩8.01b |
27.9x
P/S Ratio-14.4x
P/E RatioIs A150840 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A150840 income statement (TTM) | |
|---|---|
| Revenue | ₩8.01b |
| Cost of Revenue | ₩3.43b |
| Gross Profit | ₩4.59b |
| Other Expenses | ₩20.11b |
| Earnings | -₩15.52b |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -405.99 |
| Gross Margin | 57.23% |
| Net Profit Margin | -193.75% |
| Debt/Equity Ratio | 16.3% |
How did A150840 perform over the long term?
See historical performance and comparison